Corvus Pharmaceuticals Cash Per Share vs. Total Debt

CRVS Stock  USD 9.42  0.69  7.90%   
Based on Corvus Pharmaceuticals' profitability indicators, Corvus Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Corvus Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
0.56530651
Current Value
0.54
Quarterly Volatility
34.07046716
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Corvus Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year. Days Of Payables Outstanding is likely to gain to 3,871 in 2024, whereas Free Cash Flow Yield is likely to drop (0.30) in 2024.
For Corvus Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Corvus Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Corvus Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Corvus Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Corvus Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corvus Pharmaceuticals. If investors know Corvus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corvus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Return On Assets
(0.24)
Return On Equity
(0.45)
The market value of Corvus Pharmaceuticals is measured differently than its book value, which is the value of Corvus that is recorded on the company's balance sheet. Investors also form their own opinion of Corvus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corvus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corvus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corvus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corvus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corvus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corvus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Corvus Pharmaceuticals Total Debt vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Corvus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Corvus Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Corvus Pharmaceuticals is rated below average in cash per share category among its peers. It also is rated below average in total debt category among its peers making up about  1,126,230  of Total Debt per Cash Per Share. At this time, Corvus Pharmaceuticals' Cash Per Share is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Corvus Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Corvus Total Debt vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Corvus Pharmaceuticals

Cash Per Share

 = 

Total Cash

Average Shares

 = 
1.22 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Corvus Pharmaceuticals

Total Debt

 = 

Bonds

+

Notes

 = 
1.37 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Corvus Total Debt vs Competition

Corvus Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 172.11 Million. Corvus Pharmaceuticals maintains roughly 1.37 Million in total debt contributing less than 1% to equities under Health Care industry.
Total debt  Valuation  Revenue  Capitalization  Workforce

Corvus Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Corvus Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Corvus Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Corvus Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Corvus Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-967 K-918.6 K
Operating Income-23.3 M-24.5 M
Net Loss-30.2 M-31.7 M
Income Before Tax-27 M-28.4 M
Total Other Income Expense Net-3.7 M-3.5 M
Net Loss-37.2 M-39 M
Net Loss-27 M-28.4 M
Income Tax Expense10.1 M10.6 M
Interest Income5.4 K5.1 K
Net Interest Income1.5 M862.8 K
Non Operating Income Net Other43.7 M45.9 M
Change To Netincome8.4 M8.8 M
Net Loss(0.56)(0.59)
Income Quality 0.89  0.99 
Net Income Per E B T 1.09  0.77 

Corvus Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Corvus Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Corvus Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Corvus Pharmaceuticals' important profitability drivers and their relationship over time.

Use Corvus Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corvus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Corvus Pharmaceuticals Pair Trading

Corvus Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Corvus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corvus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corvus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corvus Pharmaceuticals to buy it.
The correlation of Corvus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corvus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corvus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corvus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Corvus Pharmaceuticals position

In addition to having Corvus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Millennials Best Thematic Idea Now

Millennials Best
Millennials Best Theme
Companies or funds that provide products or services that appeal to the generation of millennials and that are expected to experience growth in the next 5 years. The millennial generation usually refers to the demographic population that were born between 1980 to 2000. The Millennials Best theme has 77 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Millennials Best Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.